RecruitingPhase 2NCT06902974

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

Sponsor

Sunstone Medical

Enrollment

70 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Post Traumatic Stress Disorder PTSD

Summary

A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Psilocybin 25 mg for people with ptsd and post traumatic stress disorder. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.